西酞普兰合并神衰宁丸治疗脑卒中后抑郁症

目的:探讨西酞普兰合并神衰宁丸治疗脑卒中后抑郁的临床疗效。方法:将80例脑卒中后抑郁患者随机分为西酞普兰合并神衰宁丸的治疗组和西酞普兰对照组各40例,观察治疗6周。于治疗前及治疗1,2,4,6周末采用汉密顿抑郁量表(HAMD)进行抗抑郁疗效评定,用改良的爱丁堡-斯堪的纳维亚卒中量表(MESSS)进行神经功能康复评定,用治疗中出现的症状量表(TESS)评定药物不良反应。结果:HAMD和TESS评分显示,在第1和2周末治疗组和对照组区别显著(P<0.05);MESSS评分显示:在治疗6周末,治疗组(14.22±4.53)比对照组(17.38±5.10)下降显著(P<0.05)。结论:在治疗脑卒中后抑郁中,酞普兰合并神衰宁丸抗抑郁的起效更快,对神经功能的康复效果和患者的耐受性都较好。

Therapeutic Effect of Citalopram Combined with Shenshuaining Pill in Treatment of Post-stroke Depression

Objective: To study the therapeutic effect of citalopram combined with Shenshuaining pill (SSNP) in the treatment of post-stroke depression. Method: Eighty post-stroke depression patients were randomly assigned into treated (citalopram combined with SSNP) and control (citalopram) groups (each n =40) for 6 weeks.Anti-depression therapeutic effect, neural functional impairment and adverse reactions were assessed with the hamilton depression scale (HAMD), the modified Edinburgh-Scandinavia stroke scale (MESSS), and the Treatment Emergent Symptom Scale(TESS)respectively. Result: In the treatment group, the scores of the HAMD and TESS distinguished markedly at the end of the 1^st and 2^st weeks, and the total scores of the MESSS were 14.22±4.53 in treatment groups at the end of the 6th were, compared with control group(17.38±5.10), they decreased significantly distinguished( P <0.05). Conclusion: Citalopram combined with SSNP had superior therapeutic effect for neural function recovery, and was a kind of rapid and safe drug in the treatment of post-stroke depression.